In addition, NSE levels in serum are also significantly different between patients and non-patients: increased level of serum NSE (>13 ng/ml) was detected in 68% of patients with limited SCLC and 87% of patients with extensive SCLC [88]. This evidence concerns the gene ENO2 and small cell lung carcinoma.